AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34090360 — intervention group
Group type: EXPERIMENTAL
Intervention: RBF4MNH intervention sites
Number of subjects: 2772
Study 34090360 — intervention group
Group type: COMPARATOR
Intervention: Non-RBF intervention sites
Number of subjects: 2772
Study 32407514 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted higher glucagon
Number of subjects: 24
Study 35980127 — intervention group
Group type: EXPERIMENTAL
Intervention: Saddlepoint approximation method for log-rank tests
Number of subjects: 0
Study 35980127 — intervention group
Group type: COMPARATOR
Intervention: Log-rank tests for clustered data
Number of subjects: 0
Study 34774196 — intervention group
Group type: EXPERIMENTAL
Intervention: BBV152 vaccine (two intramuscular doses administered 4 weeks apart)
Number of subjects: 25798
Study 34774196 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two doses administered 4 weeks apart)
Number of subjects: 25798
Study 34774196 — intervention group
Group type: EXPERIMENTAL
Intervention: BBV152 vaccine
Number of subjects: 25798
Study 34774196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25798
Study 35511655 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenoid™ topical treatment
Number of subjects: 60
Study 35511655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34967338 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 120
Study 34967338 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosequence BC RRM putty
Number of subjects: 120
Study 34967338 — intervention group
Group type: EXPERIMENTAL
Intervention: Geristore
Number of subjects: 120
Study 34967338 — intervention group
Group type: COMPARATOR
Intervention: Without root-end filling
Number of subjects: 120
Study 34967338 — intervention group
Group type: COMPARATOR
Intervention: Intact, sound teeth
Number of subjects: 120
Study 34262151 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength or balance exercise during chemotherapy treatment
Number of subjects: 0
Study 34262151 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32851644 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 946
Study 32851644 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 946
Study 32851644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 946
Study 33707177 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 207
Study 33707177 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-β (IFN-β)
Number of subjects: 207
Study 35078841 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical airway anaesthesia combined with intravenous induction
Number of subjects: 96
Study 35078841 — intervention group
Group type: COMPARATOR
Intervention: Control group (Conventional intravenous induction without topical anaesthesia)
Number of subjects: 96
Study 33629384 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous zinc (HDIVZn)
Number of subjects: 33
Study 33629384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 32519032 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid 6MP formulation (20 mg/ml)
Number of subjects: 16
Study 32519032 — intervention group
Group type: COMPARATOR
Intervention: 6MP tablet (50 mg)
Number of subjects: 16
Study 36200875 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI scoring system for lower-extremity joint and entheseal inflammation
Number of subjects: 56
Study 33625821 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh
Number of subjects: 90
Study 33625821 — intervention group
Group type: EXPERIMENTAL
Intervention: ILMA
Number of subjects: 90
Study 33625821 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath
Number of subjects: 90
Study 33625821 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh and McGrath
Number of subjects: 90
Study 36209132 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie meal replacement shake (200 kcal) as dinner
Number of subjects: 44
Study 36209132 — intervention group
Group type: COMPARATOR
Intervention: Habitual diets (Control)
Number of subjects: 44
Study 32835607 — intervention group
Group type: EXPERIMENTAL
Intervention: EM-β-carotene (emulsion dispersion formulation)
Number of subjects: 2
Study 32835607 — intervention group
Group type: COMPARATOR
Intervention: CR-β-carotene (crystal dispersion formulation)
Number of subjects: 2
Study 32835607 — intervention group
Group type: EXPERIMENTAL
Intervention: EM-β-carotene
Number of subjects: 2
Study 32835607 — intervention group
Group type: COMPARATOR
Intervention: CR-β-carotene
Number of subjects: 2
Study 35041766 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion-based self-help
Number of subjects: 130
Study 35041766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based self-help
Number of subjects: 130
Study 34496632 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management strategy
Number of subjects: 5179
Study 34496632 — intervention group
Group type: COMPARATOR
Intervention: Conservative management strategy
Number of subjects: 5179
Study 34496632 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate ischemia
Number of subjects: 5179
Study 34496632 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe ischemia
Number of subjects: 5179
Study 34496632 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing CAD severity
Number of subjects: 5179
Study 34496632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia severity
Number of subjects: 5179
Study 33283600 — intervention group
Group type: EXPERIMENTAL
Intervention: Global FFR tertiles (low, mid, high)
Number of subjects: 1122
Study 33283600 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in global FFR by 0.1 unit
Number of subjects: 1122
Study 35105593 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleophthalmology referral pathway
Number of subjects: 24
Study 35105593 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 24
Study 35105593 — intervention group
Group type: EXPERIMENTAL
Intervention: AI decision support system (DSS)
Number of subjects: 24
Study 33773775 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate feeding rate (454 g for 42 d, and 227 g for 7 d)
Number of subjects: 100
Study 33773775 — intervention group
Group type: COMPARATOR
Intervention: High feeding rate (454 g for 7 d, 681 g for 35 d, and 341 g for 7 d)
Number of subjects: 100
Study 33773775 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% fat content in milk replacer
Number of subjects: 100
Study 33773775 — intervention group
Group type: COMPARATOR
Intervention: 24% fat content in milk replacer
Number of subjects: 100
Study 33773775 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate feeding rate (MOD)
Number of subjects: 100
Study 33773775 — intervention group
Group type: COMPARATOR
Intervention: High feeding rate (HI)
Number of subjects: 100
Study 36260325 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT increase of 7 ng/L or more
Number of subjects: 6035
Study 36260325 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT decrease of 7 ng/L or more
Number of subjects: 6035
Study 36260325 — intervention group
Group type: COMPARATOR
Intervention: Stable hsTnT values (change <3 ng/L)
Number of subjects: 6035
Study 33484628 — intervention group
Group type: EXPERIMENTAL
Intervention: HERB system + standard lifestyle modification
Number of subjects: 146
Study 33484628 — intervention group
Group type: COMPARATOR
Intervention: standard lifestyle modification alone
Number of subjects: 146
Study 35859489 — intervention group
Group type: EXPERIMENTAL
Intervention: Online lecture with PowerPoint presentation
Number of subjects: 45
Study 35859489 — intervention group
Group type: EXPERIMENTAL
Intervention: Online short film with discussion
Number of subjects: 45
Study 35859489 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-learning online booklet
Number of subjects: 45
Study 34232452 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV specific intervention
Number of subjects: 180
Study 34232452 — intervention group
Group type: COMPARATOR
Intervention: General health intervention
Number of subjects: 180
Study 33888102 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted circulating tHcy levels
Number of subjects: 14
Study 33888102 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted folate levels
Number of subjects: 14
Study 33888102 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted vitamin B6 levels
Number of subjects: 14
Study 33888102 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted vitamin B12 levels
Number of subjects: 14
Study 32306762 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive educational intervention (one-month program with three months follow-up, total four months)
Number of subjects: 120
Study 33902656 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring system (OPTIMUM)
Number of subjects: 330
Study 33902656 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 330
Study 32459420 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of oral dronabinol
Number of subjects: 70
Study 32459420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 33220297 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC)
Number of subjects: 27
Study 33220297 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorectal formalin instillation (EFI)
Number of subjects: 27
Study 32390547 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 1692157
Study 32390547 — intervention group
Group type: EXPERIMENTAL
Intervention: AF associated with SND
Number of subjects: 1692157
Study 32390547 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated sinus node disease (SND)
Number of subjects: 1692157
Study 32390547 — intervention group
Group type: COMPARATOR
Intervention: Control population with other cardiac conditions
Number of subjects: 1692157
Study 32390547 — intervention group
Group type: EXPERIMENTAL
Intervention: SND compared to AF
Number of subjects: 1692157
Study 32390547 — intervention group
Group type: EXPERIMENTAL
Intervention: SND compared to control population
Number of subjects: 1692157
Study 36286852 — intervention group
Group type: EXPERIMENTAL
Intervention: Brainmax
Number of subjects: 180
Study 36286852 — intervention group
Group type: COMPARATOR
Intervention: ethylmethylhydroxypyridine succinate
Number of subjects: 180
Study 36286852 — intervention group
Group type: COMPARATOR
Intervention: trimethylhydrazinium propionate
Number of subjects: 180
Study 33682194 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week training session on hand hygiene for children and an education program for parents (seminar and WeChat groups)
Number of subjects: 582
Study 33682194 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 582
Study 35224756 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusobacterium nucleatum (Fn) and Lachnoclostridium marker (m3)
Number of subjects: 161
Study 35224756 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostridium hathewayi (Ch)
Number of subjects: 161
Study 35224756 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of m3, Fn and Ch at follow-up
Number of subjects: 161
Study 35224756 — intervention group
Group type: COMPARATOR
Intervention: Faecal immunochemical test (FIT)
Number of subjects: 161
Study 34119499 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic cefazolin 2 g IV (Group A)
Number of subjects: 124
Study 34119499 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis + cefazolin 2 g IV × 3 followed by oral amoxicillin/clavulanate 3 g/day (Group B)
Number of subjects: 124
Study 34119499 — intervention group
Group type: COMPARATOR
Intervention: Group A (Prophylactic cefazolin 2 g IV)
Number of subjects: 124
Study 34119499 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (Prophylaxis + cefazolin 2 g IV × 3 followed by oral amoxicillin/clavulanate 3 g/day)
Number of subjects: 124
Study 34119499 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 124
Study 32293191 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-position (Mid‐p) strategy
Number of subjects: 44
Study 32293191 — intervention group
Group type: COMPARATOR
Intervention: Internal target volume (ITV) strategy
Number of subjects: 44
Study 36053803 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide
Number of subjects: 9462
Study 36053803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9462
Study 33491424 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM) patients
Number of subjects: 110
Study 33491424 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnant women (comparison group)
Number of subjects: 110
Study 34846805 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital medical history (DMH) implementation
Number of subjects: 640
Study 34846805 — intervention group
Group type: COMPARATOR
Intervention: Phone calls for DMH completion
Number of subjects: 640
Study 34846805 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and anatomic injury location
Number of subjects: 640
Study 34002562 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 60
Study 34002562 — intervention group
Group type: COMPARATOR
Intervention: Sham Electroacupuncture (sham EA)
Number of subjects: 60
Study 32779728 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 200 mg daily for 7 days
Number of subjects: 1000
Study 32779728 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline) for 7 days
Number of subjects: 1000
Study 35724252 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33483447 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet inflated
Number of subjects: 53
Study 33483447 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet not inflated
Number of subjects: 53
Study 35490404 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1831865 (3.5, 7, 17, 35, 75, or 150 mg i.v. or 150 mg s.c.)
Number of subjects: 70
Study 35490404 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1831865 i.v.
Number of subjects: 70
Study 35490404 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1831865 s.c.
Number of subjects: 70
Study 35490404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 33321441 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 504
Study 33321441 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 every 3 weeks)
Number of subjects: 504
Study 33321441 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 504
Study 33321441 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 504
Study 32833918 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge score
Number of subjects: 11657
Study 32833918 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness
Number of subjects: 11657
Study 34657999 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually set training threshold
Number of subjects: 36
Study 34657999 — intervention group
Group type: COMPARATOR
Intervention: Group averaged training threshold
Number of subjects: 36
Study 34028131 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 0
Study 34028131 — intervention group
Group type: COMPARATOR
Intervention: Contingency Management (CM)
Number of subjects: 0
Study 32060679 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat hot pack (WHP)
Number of subjects: 30
Study 32060679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pottery hot pack (PHP)
Number of subjects: 30
Study 36179382 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlling and emotional IPV
Number of subjects: 3086
Study 36179382 — intervention group
Group type: EXPERIMENTAL
Intervention: Material hardship
Number of subjects: 3086
Study 32084041 — intervention group
Group type: EXPERIMENTAL
Intervention: Family management style combined with routine care
Number of subjects: 130
Study 32084041 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 130
Study 32084041 — intervention group
Group type: EXPERIMENTAL
Intervention: Family management style
Number of subjects: 130
Study 33905902 — intervention group
Group type: COMPARATOR
Intervention: Combined administration of 2% lidocaine and 0.5% bupivacaine (20 mL mixture: 10 mL each)
Number of subjects: 97
Study 33905902 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential administration of 2% lidocaine (10 mL) followed by 0.5% bupivacaine (10 mL) after 120 s
Number of subjects: 97
Study 33905902 — intervention group
Group type: COMPARATOR
Intervention: Combined administration of 2% lidocaine and 0.5% bupivacaine
Number of subjects: 97
Study 33905902 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential administration of 2% lidocaine and 0.5% bupivacaine
Number of subjects: 97
Study 34882430 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD group
Number of subjects: 1116
Study 32438624 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii CNCM I‐1079
Number of subjects: 50
Study 32438624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 34001185 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track clinical pathway
Number of subjects: 90
Study 34001185 — intervention group
Group type: COMPARATOR
Intervention: Standard care protocol
Number of subjects: 90
Study 32065258 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-min stair climbing every hour during a 4-h sitting period
Number of subjects: 12
Study 32065258 — intervention group
Group type: COMPARATOR
Intervention: 4-h uninterrupted sitting
Number of subjects: 12
Study 34813038 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of mesenteric defects (n=150)
Number of subjects: 300
Study 34813038 — intervention group
Group type: COMPARATOR
Intervention: Nonclosure of mesenteric defects (n=150)
Number of subjects: 300
Study 34813038 — intervention group
Group type: EXPERIMENTAL
Intervention: Total radiation dose in closure group
Number of subjects: 300
Study 34813038 — intervention group
Group type: COMPARATOR
Intervention: Total radiation dose in nonclosure group
Number of subjects: 300
Study 32193692 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower physical activity level
Number of subjects: 185
Study 32193692 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower age
Number of subjects: 185
Study 32193692 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity level and age
Number of subjects: 185
Study 32193692 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph‐ICF‐UL questionnaire
Number of subjects: 185
Study 34210209 — intervention group
Group type: EXPERIMENTAL
Intervention: Light gradient boosting machines prediction model
Number of subjects: 487
Study 34210209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases of ICP
Number of subjects: 487
Study 34210209 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 487
Study 34839603 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial dermis+split-thickness skin
Number of subjects: 82
Study 34839603 — intervention group
Group type: COMPARATOR
Intervention: Flap
Number of subjects: 82
Study 36220325 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental therapeutics (specifics not provided)
Number of subjects: 20
Study 33811400 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% phytic acid solution and AH Plus sealer
Number of subjects: 40
Study 33811400 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% phytic acid solution and EndoSequence BC sealer
Number of subjects: 40
Study 33811400 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA solution and AH Plus sealer
Number of subjects: 40
Study 33811400 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA solution and EndoSequence BC sealer
Number of subjects: 40
Study 32251400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus Nivolumab (20 dMMR tumors)
Number of subjects: 40
Study 32251400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab plus Nivolumab (15 pMMR tumors)
Number of subjects: 40
Study 32251400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy (3 patients in safety run-in)
Number of subjects: 40
Study 34060166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine cream
Number of subjects: 120
Study 34060166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 120
Study 34060166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutaneous stimulation therapy
Number of subjects: 120
Study 34060166 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 120
Study 34410847 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 13
Study 34410847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 32365849 — intervention group
Group type: EXPERIMENTAL
Intervention: Perilla frutescens leaf powder (PLP)
Number of subjects: 60
Study 32365849 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pectin fiber)
Number of subjects: 60
Study 36314372 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE)
Number of subjects: 742
Study 36314372 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 742
Study 32636205 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving up to four bi‐weekly email reminders to translate PLSs
Number of subjects: 80
Study 32636205 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 80
Study 32118696 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low-dose carbon monoxide (CO) administration
Number of subjects: 22
Study 32118696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 36042146 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted renal sympathetic denervation (RDN)
Number of subjects: 0
Study 36042146 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0
Study 34399066 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina supplementation (6 g/day for 21 days)
Number of subjects: 15